Gilead Slumps As Long-Term Uncertainty Clouds Big HIV Beat

Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability

Gilead's Yeztugo injection hit $232M in Q2 2026 with 70%+ persistence, leading the PrEP switch market in four quarters. The parallel weekly oral formulation—tacitly admitting 80-85% prefer oral convenience—signals Yeztugo durability risks and a capped injectable TAM versus consensus.